1 December 2005   
News
Executive Vice President's Message
CLSI 2005 Survey Results Reflect Market Views, Needs
Announcing 2006 Leadership Conference
CLSI Honor Roll and 2006 Awards Nominations
Press Releases
Standards Status
Vote and Deadlines
Recently Approved Documents
Call for Nominations
Events and Exhibits
Upcoming Events
Upcoming Presentations
CLSI Meetings Calendar
Participate in CLSI
Volunteer
New and Sustaining Members
Update Your Subscription
 
CLSI Home Page
Search Past Issues
Update Your Contact Information
Print this article Print all articles
 
 
 
Winner of the Silver Award for Patient Education in the WWW Health Awards Program

Recently Approved Documents
Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data; Approved Guideline—Second Edition (M39-A2)

M39-A2Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data; Approved Guideline—Second Edition 
This document provides guidelines for clinical laboratories and their data analysis software providers on the routine generation and storage of susceptibility data, and the compilation of susceptibility statistics.  M39-A2 provides recommendations for consistent and effective use of cumulative susceptibility statistics, to enable clinicians to select the most appropriate agents for empiric antimicrobial therapy.  Updates include expanded rationale behind including only the "first isolate per patient" in analyzing data; guidelines for data presentation; and expanded guidelines for presenting data to reflect new resistance trends.
Purchase here.

Second Notice

EP7-A2Interference Testing in Clinical Chemistry; Approved Guideline—Second Edition
Promoting uniformity in evaluating interference characteristics in clinical laboratory measurement procedures, EP7 describes procedures for manufacturers to screen potentially interfering substances, quantify interference effects, and confirm interference in patient samples. The guideline also describes procedures for clinical laboratories to verify interference claims, and to investigate discrepant results caused by unsuspected interfering substances.  Includes background information on interference testing concepts, tables of recommended test concentrations for analytes and potential interference, and data collection and analysis worksheets.
Purchase here.


Our procedures have been designed to ensure that consensus has been achieved when a standard or guideline is published at the approved level. This means that a document has been rigorously reviewed by the authoring subcommittee, the area committee overseeing the project, the Board of Directors, and the medical-testing community that participates in the consensus process by carefully reviewing and commenting on the standard or guideline.

You may automatically receive or select approved-level documents as a member benefit.  Find out more about joining CLSI:  view membership options and benefits. 


 

[ return to top ]

For more information or to contact us directly, please visit www.clsi.org
©2005 Clinical and Laboratory Standards Institute